• The world’s first non-surgical, non-invasive therapy for patients with cervical intraepithelial neoplasia grade 2 (CIN2)

• The marketing authorization application (MAA) for CEVIRA® was accepted for review by the European Medicines Agency (EMA) in February 2026

• The company has also reached an agreement with the U.S. FDA on the design of a separate Phase III trial to support CEVIRA®’s potential U.S. approval

* CEVIRA® is a registered trademark of PHOTOCURE